Clinical Research Advances of Duodenal-Type Follicular Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2023.02.039
- Author:
Hong-Yi LI
1
,
2
;
Jun-Dong ZHANG
1
,
2
;
Xue-Chun LU
1
,
3
Author Information
1. Medical School of Chinese PLA
2. Department of Hematology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Geriatric Disease, Beijing 100853, China.
3. Department of Hematology, The Second Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Geriatric Disease, Beijing 100853, China .E-mail: luxuechun@126.com.
- Publication Type:Journal Article
- Keywords:
duodenal follicular lymphoma;
duodenal lymphoma;
follicular lymphoma;
prognosis;
treatment
- MeSH:
Humans;
Lymphoma, Follicular/drug therapy*;
Duodenal Neoplasms/pathology*;
Prognosis;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2023;31(2):581-584
- CountryChina
- Language:Chinese
-
Abstract:
Duodenal-type follicular lymphoma (DFL) is a unique subtype of follicular lymphoma (FL), which often involves the second portion of duodenum (descending part of duodenum). Due to its specific pathological features, such as lack of follicular dendritic cells meshwork and disappearance of activation-induced cytidine deaminase expression, DFL presents an inert clinical course and is often confined to the intestinal tract. Inflammation-related biomarkers suggest that the microenvironment may play a likely role in the pathogenesis and favorable prognosis of DFL. Since patients generally have no obvious clinical symptoms and low progression rate, the treatment regimen for DFL is mainly observation and waiting (W&W) strategy. This study will review the latest research progress of epidemiology, diagnosis, treatment and prognosis of DFL in recent years.
